DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?

Shares of DaVita (DVA) have risen 17.1% in the past three months, outperforming the Zacks Medical - Outpatient and Home Healthcare industry's growth of 13.5% and the broader Zacks Medical sector's return of 2.5%. DVA stock has risen 54.8% year to date, primarily due to rising demand for its dialysis services. The uptrend is likely to continue for the rest of 2024 and beyond as there should be a rising demand for dialysis services due to an expanding patient pool with end-stage renal diseases. Per a report, ...